https://www.selleckchem.com/pr....oducts/tefinostat.ht
2%). In 15 (29.4%) studies, mortality was the most frequently reported PIO; 11 (21.5%) studies evaluated at least one PIO other than mortality, quality of life being this PIO in 6. PIOs were described in half of prospective articles dealing with adult LTx recipients published in 2019. Outcomes other than mortality were insufficiently considered. A core outcome set of PIOs in LTx should be developed with patient input to guide future research in LTx. PIOs were described in half of prospective articles dealing with adult LTx recipients
Like
Comment
Share
